Allogene Therapeutics, Inc. (ALLO) — Financial statements
Income statement, balance sheet, and cash flow for Allogene Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00↓100.0% | 0.02↓76.8% | 0.10↓39.1% | 0.16↓99.9% | 114 | |
| Cost of Revenue | 12 | 0.00 | 0.00↓100.0% | 14 | 0.00 | |
| Gross Profit | -12↓56277.3% | 0.02↓76.8% | 0.10↑100.7% | -14↓112.4% | 114 | |
| Operating Expenses | ||||||
| R&D Expenses | 150↓21.9% | 192↓20.8% | 243↓5.3% | 256↑16.4% | 220 | |
| General & Administrative Expenses | 57↓12.9% | 65↓9.0% | 72↓9.6% | 79↑7.0% | 74 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 57↓12.9% | 65↓9.0% | 72↓9.6% | 79↑7.0% | 74 | |
| Other Expenses | -12↓178.6% | 16↑18.7% | 13↑192.7% | -14 | 0.00 | |
| Operating Expenses | 195↓28.8% | 273↓16.7% | 328↑2.0% | 321↑9.2% | 294 | |
| Total Costs & Expenses | 207↓24.3% | 273↓16.7% | 328↓2.3% | 336↑14.1% | 294 | |
| Operating Results | ||||||
| Operating Income | -207↑24.3% | -273↑16.6% | -328↑2.3% | -336↓86.2% | -180 | |
| Depreciation & Amortization | 12↓9.4% | 14↓3.9% | 14↓0.7% | 14↑36.7% | 10 | |
| EBITDA | -195↑20.0% | -243↑22.3% | -313↑2.5% | -321↓89.3% | -170 | |
| EBIT | -207↑19.5% | -257↑21.5% | -327↑2.5% | -336↓86.2% | -180 | |
| Interest & Other Income | ||||||
| Net Interest Income | 18↓8.8% | 20↑9.1% | 18↑300.9% | 5↑166.4% | 2 | |
| Interest Income | 19↓4.3% | 20↑10.1% | 18↑300.9% | 5↑166.4% | 2 | |
| Interest Expense | 1↑493.9% | 0.18 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -16↓3339.2% | -0.47 | 0.00 | 0.00 | |
| Other Income / Expenses | 16↓0.0% | 16↑3300.8% | 0.47↑109.7% | -5↓162.4% | -2 | |
| Income Before Tax | -191↑25.8% | -257↑21.4% | -327↑3.9% | -340↓87.0% | -182 | |
| Income Tax Expense | 0.00↓100.0% | 0.44 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -191↑25.9% | -258↑21.3% | -327↑3.9% | -340↓87.0% | -182 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -191↑25.9% | -258↑21.3% | -327↑3.9% | -340↓87.0% | -182 | |
| Bottom-Line Net Income | -191↑25.9% | -258↑21.3% | -327↑3.9% | -340↓87.0% | -182 | |
| EPS (Basic) | -0.87↑34.1% | -1.32↑36.8% | -2.09↑12.2% | -2.38↓77.6% | -1.34 | |
| EPS (Diluted) | -0.87↑34.1% | -1.32↑36.8% | -2.09↑12.2% | -2.38↓77.6% | -1.34 | |
| Weighted Average Shares | 221↑13.2% | 195↑24.1% | 157↑9.6% | 143↑5.4% | 136 | |
| Weighted Average Diluted Shares | 221↑13.2% | 195↑24.1% | 157↑9.6% | 143↑5.4% | 136 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.